HUTCHMED (China) (HMDCF) Total Non-Current Liabilities (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Total Non-Current Liabilities came in at $363.6 million in Q2 2026, up 6072.78% year-over-year from $5.9 million in Q2 2025, and up 7222.8% quarter-over-quarter from $5.0 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Total Non-Current Liabilities for 12 consecutive years, with $363.6 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 6072.78% year-over-year to $363.6 million in Q2 2026; TTM through Jun 2026 was $363.6 million, a 6072.78% increase from a year earlier, with the FY2025 full-year figure at $5.0 million, up 28.69% from the prior year.
- Total Non-Current Liabilities was $363.6 million for Q2 2026 at HUTCHMED (China), up from $5.0 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $478.2 million in Q2 2023 and troughed at $3.7 million in Q4 2023.
- A 5-year average of $97.2 million and a median of $5.0 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities jumped 7835.38% in 2023 and plunged 99.16% in 2024, its largest moves.
- Over 5 years, Total Non-Current Liabilities stood at $4.9 million in 2022, then slipped by 25.42% to $3.7 million in 2023, then grew by 4.64% to $3.9 million in 2024, then increased by 28.69% to $5.0 million in 2025, then surged by 7222.8% to $363.6 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $363.6 million (Q2 2026), $5.0 million (Q4 2025), and $5.9 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | 378.37 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 363.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 363.58 Mn |
| Dec 31, 2025 | 4.97 Mn |
| Jun 30, 2025 | 5.89 Mn |
| Dec 31, 2024 | 3.86 Mn |
| Jun 30, 2024 | 4.03 Mn |
| Dec 31, 2023 | 3.69 Mn |
| Jun 30, 2023 | 478.19 Mn |
| Dec 31, 2022 | 4.94 Mn |
| Jun 30, 2022 | 6.03 Mn |
| Dec 31, 2021 | 7.13 Mn |
| Jun 30, 2021 | 28.67 Mn |
| Mar 31, 2021 | 221.92 Mn |
| Dec 31, 2020 | 16.03 Mn |
| Jun 30, 2020 | -37.62 Mn |
| Dec 31, 2019 | -48.69 Mn |
| Sep 30, 2019 | 108.85 Mn |
| Jun 30, 2019 | 114.32 Mn |
| Mar 31, 2019 | 130.61 Mn |
| Dec 31, 2018 | 17.30 Mn |
| Jun 30, 2018 | 117.25 Mn |